# mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer

> **NCT05200299** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital of Wenzhou Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** mFOLFOXIRI
- **DRUG:** mFOLFOX6 OR CapeOx

## Key facts

- **NCT ID:** NCT05200299
- **Lead sponsor:** First Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05200299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05200299, "mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05200299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*